Luca Federici

Dr. Luca Federici

Department of Medical, Oral and Biotechnological Sciences, Ce.S.I.-­‐MeT Center for Studies on Ageing and Translational Medicine, University of Chieti "G. d'Annunzio", Via dei vestini 31-­66013 Chieti, Italy

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2006 in Trends in Plant Science
Verified
Journal Article
Closed access
LFLuca Federici
Luca Federici
AMAdele Di Matteo
Adele Di Matteo
JFJuan Fernandez-Recio
Juan Fernandez-Recio
DTDemetrius Tsernoglou
Demetrius Tsernoglou
FCFelice Cervone
Felice Cervone

18 March 2013 in Protein Science
Verified
Journal Article
Closed access
PDF file
LFLuca Federici
Luca Federici
‪‪‪Brunangelo ‪Falini
‪Brunangelo ‪Falini

16 January 2013 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
SCSara Chiarella
Sara Chiarella
ACAntonella De Cola
Antonella De Cola
GSGiovanni Luca Scaglione
Giovanni Luca Scaglione
ECErminia Carletti
Erminia Carletti
VGVincenzo Graziano
Vincenzo Graziano
LFLuca Federici
Luca Federici
Nucleophosmin (NPM1) is an abundant nucleolar protein implicated in ribosome maturation and export, centrosome duplication and response to stress stimuli. NPM1 is the most frequently mutated gene in acute myeloid leukemia. Mutations at the C-terminal domain led to variant proteins that aberrantly and stably translocate to the cytoplasm. We have previously shown that NPM1 C-terminal domain binds with high affinity G-quadruplex DNA. Here, we investigate the structural determinants of NPM1 nucleolar localization. We show that NPM1 interacts with several G-quadruplex regions found in ribosomal DNA, both in vitro and in vivo . Furthermore, the most common leukemic NPM1 variant completely loses this activity. This is the consequence of G-quadruplex–binding domain destabilization, as mutations aimed at refolding the leukemic variant also result in rescuing the G-quadruplex–binding activity and nucleolar localization. Finally, we show that treatment of cells with a G-quadruplex selective ligand results in wild-type NPM1 dislocation from nucleoli into nucleoplasm. In conclusion, this work establishes a direct correlation between NPM1 G-quadruplex binding at rDNA and its nucleolar localization, which is impaired in the acute myeloid leukemia-associated protein variants.

Verified
Journal Article
Open access
PDF file
Ilaria CicaliniIlaria Cicalini
Ilaria Cicalini
Claudia RossiClaudia Rossi
Claudia Rossi
Damiana PieragostinoDamiana Pieragostino
Damiana Pieragostino
LALuca Agnifili
Luca Agnifili
LMLeonardo Mastropasqua
Leonardo Mastropasqua
PIERO DEL BOCCIOPIERO DEL BOCCIO
PIERO DEL BOCCIO
Metabolomics based on mass spectrometry represents an innovative approach to characterize multifactorial diseases, such as multiple sclerosis (MuS). To date, the most important biomarker source for MuS diagnosis is the cerebrospinal fluid. However, an important goal for research is to identify new molecules in more easily accessible biological fluids. A very interesting biofluid in MuS is represented by tears, considered as an intermediate fluid between the cerebrospinal fluid and serum. In this work, we developed a merged strategy for the analysis of lipids containing choline by Liquid Chromatography coupled to Tandem Mass Spectrometry (LC-MS/MS), as well as for the targeted analysis of free carnitine, acylcarnitines and aminoacids by direct infusion mass spectrometry. Samples for both metabolomics and lipidomics approaches were obtained in a single extraction procedure from tears of patients affected by MuS and healthy controls. Tear lipidomics showed 30 phospholipids significantly modulated and, notably, many sphingomyelins resulted lower in MuS. Moreover, the metabolomics approach carried out both on tears and serum highlighted the diagnostic potential of specific aminoacids and acylcarnitines. In conclusion, the metabolic profiling of tears appears to reflect the pathological conditions of the central nervous system, suggesting that the molecular repository of tears can be considered as a source of potential biomarkers for MuS.

14 October 2009 in Cancer Research
Verified
Journal Article
Open access
PDF file
LFLuca Federici
Luca Federici
CSCarlo Lo Sterzo
Carlo Lo Sterzo
SPSilvia Pezzola
Silvia Pezzola
AMAdele Di Matteo
Adele Di Matteo
FSFlavio Scaloni
Flavio Scaloni
ACANNA MARIA CACCURI
ANNA MARIA CACCURI
Glutathione S-transferases (GST) constitute a superfamily of enzymes with diversified functions including detoxification from xenobiotics. In many human cancers, Pi class GST (GSTP1-1) is overexpressed and contributes to multidrug resistance by conjugating chemotherapeutics. In addition, GSTP1-1 displays antiapoptotic activity by interacting with c-Jun NH2-terminal kinase, a key regulator of apoptosis. Therefore, GSTP1-1 is considered a promising target for pharmaceutical treatment. Recently, a potent inhibitor of GSTs, 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX), was identified and tested on several tumor cell lines demonstrating high antiproliferative activity. To establish the structural basis of NBDHEX activity, we determined the crystal structure of NBDHEX bound to either GSTP1-1 or GSTM2-2 (mu class). NBDHEX in both cases binds to the H-site but occupies different positions. Furthermore, the compound is covalently attached to the GSH sulfur in the GSTM2-2 crystal, forming a σ-complex, although it is bound but not conjugated in the GSTP1-1 crystal. Several differences in the H-sites of the two isozymes determine the higher affinity of NBDHEX for GSTM2-2 with respect to GSTP1-1. One such difference is the presence of Ile104 in GSTP1-1 close to the bound NBDHEX, whereas the corresponding position is occupied by an alanine in GSTM2-2. Mutation of Ile104 into valine is a frequent GSTP1-1 polymorphism and we show here that the Ile104Val and Ile104Ala variants display a 4-fold higher affinity for the compound. Remarkably, the GSTP1-1/Ile104Ala structure in complex with NBDHEX shows a considerable shift of the compound inside the H-site. These data might be useful for the development of new anticancer compounds. [Cancer Res 2009;69(20):8025–34]

5 April 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
AMAdele Di Matteo
Adele Di Matteo
MFMimma Franceschini
Mimma Franceschini
SCSara Chiarella
Sara Chiarella
SRSerena Rocchio
Serena Rocchio
CTCarlo Travaglini-Allocatelli
Carlo Travaglini-Allocatelli
LFLuca Federici
Luca Federici
Molecules that target nucleophosmin for cancer treatment: an update